Ashkan M. Abbey, MD, Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the
read more
Rajiv Anand, MD, and Ashkan Abbey, MD, Receive Senior Honor Awards from the American Society of Retina Specialists (ASRS)
In recognition of their time and contributions to the scientific programs of the organization’s annual meetings, Texas Retina’s Rajiv Anand, MD, and Ashkan M. Abbey, MD, recently earned the Senior Honor Award
read more
Dr. Abbey Recognized as a 2023 Top 10 Reviewer for Ophthalmic Surgery Lasers + Imaging Retina Medical Journal
The medical journal Ophthalmic Surgery Lasers + Imaging Retina (OSLI Retina) recently recognized Texas Retina Associates’ Ashkan M. Abbey, MD as a “2023 Top 10 Reviewer” in recognition of the quantity, quality
read more
Dr. Abbey Taught a Course at the American Academy of Ophthalmology 2023 Annual Meeting
On November 6, Texas Retina Associates’ Ashkan M. Abbey, MD, taught a continuing medical education (CME) course titled, “Secondary IOL Techniques for Retinal Specialists,” at AAO 2023, the annual meeting of the
read more
Dr. Abbey Presented at the American Society of Retina Specialists 2023 Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, recently presented at the 41st Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) held in Seattle. ASRS is the largest organization of
read more
Dr. Abbey Presents Phase 1 DAVIO Clinical Trial Results to the Association for Research in Vision and Ophthalmology
Dr. Abbey presented the results from the Phase 1 DAVIO trial at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human
read more Dr. Abbey Contributes to Real-world Study of Faricimab for Neovascular Age-related Macular Degeneration
The TRUCKEE study is a real-world, collaborative effort to investigate the efficacy, durability, and safety of a monoclonal antibody treatment called faricimab in patients suffering from neovascular age-related macular degeneration (nAMD) in
read more
Dr. Abbey Featured in New Retina Radio Podcast
Texas Retina Associates’ Ashkan M. Abbey, MD, was featured in a recently released New Retina Radio podcast for retina surgeons titled “Tips for Mastering Secondary IOLs.” Dr. Abbey discussed approaches to implanting
read more
Retina Today Publishes Dr. Abbey’s Research on a Potential Toxic Side Effect of Some “Dropless” Cataract Surgery
“Dropless” cataract surgery has become more popular over the past decade and involves an injection of antibiotics and/or steroids into the eye at the time of surgery to eliminate the need for
read more Dr. Abbey Presented at the American Academy of Ophthalmology 2022 Meeting
Over the weekend, Texas Retina Associates’ Ashkan M. Abbey, MD, taught a course titled “Secondary Intraocular Lens (IOL) Techniques for Retina Specialists” at the American Academy of Ophthalmology (AAO) 2022 meeting in Chicago,
read more